afatinib + carboplatin + pemetrexed

The combination of afatinib, carboplatin, and pemetrexed is a therapeutic regimen being studied for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations who have developed resistance to first-line treatments like osimertinib. ## Clinical Development This combination has been evaluated in both Phase I and Phase II clinical trials. A Phase I study established the recommended dose of afatinib as 20 mg/day (administered on days 8-18) when combined with carboplatin (AUC=5) and pemetrexed (500 mg/m²). This dosing schedule was designed to minimize overlapping gastrointestinal toxicities between afatinib and the chemotherapy agents. The NEJ025B Phase II trial investigated this combination in patients with EGFR mutation-positive non-squamous advanced NSCLC who had become refractory to first-line osimertinib treatment. This study enrolled 36 patients between June 7, 2020, and January 19, 2022, with 35 patients evaluated for efficacy. The primary endpoint of 6-month progression-free survival rate (6M-PFSR) was 57.1%, exceeding the threshold of 35%, thus meeting the study's primary endpoint. ## Efficacy The combination demonstrated promising clinical outcomes: - Overall response rate (ORR): 48.6% - Disease control rate (DCR): 88.6% - Median progression-free survival (PFS): 8.2 months - Median duration of response (DOR): 5.6 months - Median overall survival (OS): not reached at the time of reporting Notably, 24.1% of patients achieved long-term PFS of 1 year or longer. Response rates were similar between patients with different EGFR mutation types (Del19: 46.7%, L858R: 50.0%), though median PFS tended to be longer for Del19 mutations (9.6 months vs. 5.2 months). ## Safety Profile The most common adverse events observed with this combination included: - Diarrhea (52.8%) - Anorexia (44.4%) - Fatigue (33.3%) - Paronychia (36.1%) These adverse events were described as predictable and manageable. Interstitial pneumonia developed in three patients (8%), with one case resulting in the only death reported in the NEJ025B study. Other notable adverse events included neutropenia, thrombocytopenia, and hypokalemia. Despite these toxicities, the combination was generally considered well-tolerated at the recommended dose. ## Mechanism and Rationale The combination leverages afatinib's activity as a second-generation EGFR-TKI with the cytotoxic effects of carboplatin and pemetrexed. Recent research suggests this combination may effectively suppress thrombospondin-1 (TSP-1) expression, which could be a mechanism for overcoming osimertinib resistance in EGFR-mutated NSCLC. Based on the promising results from these studies, this regimen is considered a potential candidate for second-line therapy after osimertinib failure in EGFR-mutated NSCLC patients.